Sanofi (ETR:SNW)
85.43
-0.09 (-0.11%)
Nov 7, 2025, 5:35 PM CET
Sanofi Revenue
Sanofi had revenue of 13.17B EUR in the quarter ending September 30, 2025, a decrease of -6.97%. This brings the company's revenue in the last twelve months to 45.93B, down -5.19% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.93B
Revenue Growth
-5.19%
P/S Ratio
2.26
Revenue / Employee
554.20K
Employees
82,878
Market Cap
103.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 46.17B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.22B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
Sanofi News
- 2 days ago - Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised - Nasdaq
- 2 days ago - REGN: Regeneron and Sanofi Report Positive Dupixent Trial Results - GuruFocus
- 2 days ago - Regeneron and Sanofi's Dupixent succeeds in late-stage study - Seeking Alpha
- 2 days ago - Sanofi And Regeneron's Dupixent Meets Primary Goal In Phase 3 Allergic Fungal Rhinosinusitis Study - Nasdaq
- 2 days ago - Sanofi (SNY) Shares Encouraging Phase 3 Results for Dupixent in AFRS Patients - GuruFocus
- 2 days ago - Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review - Wallstreet:Online
- 2 days ago - Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review - Benzinga
- 2 days ago - Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review - GlobeNewsWire